1967年以来,由意大利Lepetit公司与瑞士Ciba-Geigy合作开发的半合成抗生素利福平(1)已成为特别是第三世界治疗结核病(TB)的最重要口服药之一。药物联合治疗包括异烟肼、吡嗪酰胺、乙胺丁醇或链霉素,疗程6～9个月,有效率可超过98%。虽然利福平是许多短程治疗中不可缺少的药物之一,但价格昂贵,且被盲目用于其它感染,特 Since 1967, rifampicin (1), a semi-synthetic antibiotic developed by the Italian company Lepetit in cooperation with Ciba-Geigy, Switzerland, has become one of the most important oral medicines for the treatment of tuberculosis (TB), especially in the Third World. Drug combination therapy includes isoniazid, pyrazinamide, ethambutol or streptomycin, treatment of 6 to 9 months, the effective rate can be more than 98%. Although rifampicin is one of the indispensable medicines for many short-range treatments, it is expensive and blindly used for other infections, especially